Cumulative studies indicate that CDCA3 is abnormally high expressed in multiple human malignancies, such as glioma (Han et al., 2024), prostate cancer (Gu et al., 2023), pan-renal cell carcinoma (Luo et al., 2024), and bladder cancer (Shen et al., 2025), which may contribute to tumor progression as an oncogene. Here, CDCA3 is linked to prostate carcinoma.